What the FDA labels say about taking them together
Loperamide and panitumumab
Panitumumab's FDA label of June 23, 2026 names loperamide in its warnings and precautions section; the loperamide label PlainMeds reads does not name panitumumab. The panitumumab label: “Monitor patients for diarrhea and dehydration, provide supportive care as needed, and withhold Vectibix if necessary.”
Check it at the source: the loperamide FDA label on DailyMed (effective June 3, 2026, Aurobindo Pharma Limited); the panitumumab FDA label on DailyMed (effective June 23, 2026, Amgen, Inc).
What does the loperamide label say about panitumumab?
Loperamide's label (effective June 3, 2026) does not name panitumumab in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Loperamide Hydrochloride), Aurobindo Pharma Limited, effective June 3, 2026 (SPL set 8e4004be-bf79-4631-9e38-c4e7b6726313), via openFDA; the full label on DailyMed
What does the panitumumab label say about loperamide?
Panitumumab label, warnings and precautionsMonitor patients for diarrhea and dehydration, provide supportive care (including anti-emetic or anti-diarrheal therapy) as needed, and withhold Vectibix if necessary.
Source: FDA drug label (Vectibix), Amgen, Inc, effective June 23, 2026 (SPL set e0fa4bca-f245-4d92-ae29-b0c630a315c2), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Loperamide | Panitumumab | |
|---|---|---|
| Labeled for | Diarrhea | Colorectal cancer |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $0.0549 per capsule 2 mg capsule | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once